Article
Immunology
Yibo Zhan, Min Zhao, Xiaojun Li, Huiying Ouyang, Chenghao Du, Guixian Chen, Zhenzhen Lou, Haoxuan Chen, Yuanqi Zhao, Haoyou Xu
Summary: This case report presents a patient with refractory neuromyelitis optica spectrum disorder (NMOSD) who responded poorly to multiple immunosuppressants but was successfully treated with Ofatumumab. Despite previous treatment with various therapies, the patient experienced adverse events and relapses. Ofatumumab was administered, resulting in symptom stability and no recurrence or adverse events.
FRONTIERS IN IMMUNOLOGY
(2023)
Review
Pharmacology & Pharmacy
Connie Kang, Hannah A. Blair
Summary: Ofatumumab is a fully human anti-CD20 monoclonal antibody approved for treating relapsing forms of MS. Clinical trials have shown it to be more effective than teriflunomide in reducing relapse rates and slowing disability progression, with generally manageable tolerability. It is a convenient treatment option for adults with relapsing forms of MS.
Article
Immunology
Jan-Lukas Forde, Lars Herfindal, Kjell-Morten Myhr, Oivind Torkildsen, Tom Eirik Mollnes, Silje Skrede
Summary: This study compared the complement activation of ocrelizumab, ofatumumab, and rituximab. The results showed that ofatumumab, ocrelizumab, and infliximab could trigger complement activation, while rituximab and adalimumab did not have this potential. These findings are important for understanding the differences in anti-CD20 mAbs used in the treatment of multiple sclerosis.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2023)
Article
Immunology
Simon Faissner, Neele Heitmann, Carlos Plaza-Sirvent, Paulina Trendelenburg, Ulas Ceylan, Jeremias Motte, Clara Bessen, Doris Urlaub, Carsten Watzl, Oliver Overheu, Anke Reinacher-Schick, Kerstin Hellwig, Stephanie Pfaender, Ingo Schmitz, Ralf Gold
Summary: This study investigated the immune cell alterations and immune response in patients receiving early ofatumumab treatment and compared them to healthy controls following SARS-CoV-2 vaccination. The results showed that ofatumumab treatment led to depletion of B cells and changes in certain T cell subpopulations. The humoral immune response to SARS-CoV-2 was impaired, while the cellular immune response was preserved.
FRONTIERS IN IMMUNOLOGY
(2022)
Review
Hematology
Muhammad Hossein Ashoub, Amirreza Naseri, Parisa Mohammadi, Masoud Mohammadi
Summary: The therapeutic impact of ofatumumab on patients with chronic lymphocytic leukemia (CLL) has been widely studied. However, there is a lack of pooled assessment on the treatment effect of ofatumumab compared to non-ofatumumab regimens. This meta-analysis evaluated the efficacy of ofatumumab-based treatment using data from clinical studies and found that there was a significant improvement in progression-free survival (PFS) but no significant difference in overall survival (OS) between ofatumumab-based therapy and non-ofatumumab therapy.
ANNALS OF HEMATOLOGY
(2023)
Article
Immunology
Shugang Cao, Jing Du, Sidi Pan, Juanjuan Zhang, Si Xu, Ling Wei, Yanghua Tian
Summary: This article presents a case of refractory GFAP astrocytopathy that showed poor response to conventional immunosuppressants and rituximab, but responded well to subcutaneous ofatumumab. The findings suggest the potential efficacy of ofatumumab in treating GFAP astrocytopathy patients who are intolerant to rituximab.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Mark S. Longtine, Kyuhwan Shim, Mark J. Hoegger, Nadia Benabdallah, Diane S. Abou, Daniel L. J. Thorek, Richard L. Wahl
Summary: Immunotherapy targeting CD20 protein has shown improved clinical outcomes in non-Hodgkin lymphoma, but relapse is common. In this study, we found that 225Ac-labeled anti-CD20 treatment exhibited significant cell-killing effects and therapeutic efficacy in a murine model of lymphoma.
JOURNAL OF NUCLEAR MEDICINE
(2023)
Article
Immunology
Rui Zhang, Li Wang, Yongli Tao, Xiaofeng Zhang, Kai Liu, Bo Song, Yuming Xu
Summary: The phenotypic spectrum of MOG-IgG-associated disorders has expanded, including atypical phenotypes such as isolated seizures and MRI-negative brainstem and cerebellar symptoms. Coexistence of MOG IgG and other CNS autoimmune antibodies is rare. This report describes a patient with epileptic onset followed by MRI-negative brainstem symptoms and encephalitis, positive for MOG IgG throughout the disease course with later detection of NMDAR IgG. The patient showed decreasing response to conventional therapy but ultimately responded to subcutaneous ofatumumab, highlighting its potential as a therapeutic option.
FRONTIERS IN IMMUNOLOGY
(2023)
Article
Radiology, Nuclear Medicine & Medical Imaging
Kyuhwan Shim, Mark S. Longtine, Diane S. Abou, Mark J. Hoegger, Richard S. Laforest, Daniel L. J. Thorek, Richard L. Wahl
Summary: In this study, the third-generation human anti-CD20 antibody ofatumumab was labeled with Lu-177 and showed favorable in vitro characteristics and therapeutic efficacy in a murine model of disseminated NHL. The results indicate that [Lu-177]Lu-ofatumumab has potential for clinical translation to treat NHL.
JOURNAL OF NUCLEAR MEDICINE
(2023)
Article
Rheumatology
S. B. Ali, C. Yuson, P. Hissaria
Summary: B-cell depleting agents, including rituximab, play a crucial role in various diseases but may also lead to hypersensitivity reactions. In addition to classic hypersensitivity reactions, infusion-related reactions can occur with rituximab.
CLINICAL AND EXPERIMENTAL RHEUMATOLOGY
(2021)
Article
Immunology
Julia Baguna Torres, Jay Roodselaar, Megan Sealey, Marina Ziehn, Marc Bigaud, Rainer Kneuer, David Leppert, Gisbert Weckbecker, Bart Cornelissen, Daniel C. Anthony
Summary: This study investigated the distribution and efficacy of ofatumumab and ocrelizumab in huCD20 transgenic mice, revealing differences in tissue distribution patterns between subcutaneous and intravenous administration, with the possibility of more direct access to lymph nodes through the lymphatic system with subcutaneous administration. Additionally, preliminary findings suggest that ofatumumab may be more effective than ocrelizumab at controlling MS-like pathology in the brain.
FRONTIERS IN IMMUNOLOGY
(2022)
Article
Oncology
Roger M. Lyons, Mikhail Shtivelband, Edwin Kingsley, Mehdi Moezi, Donald Richards, Jeff Sharman, Xiaoshu Feng, Megan Cannan, Rafik Fellague-Chebra, Thomas E. Boyd
Summary: Ofatumumab in combination with bendamustine showed efficacy in treating iNHL patients, with an overall response rate of 67.3% at the end of induction therapy. Treatment-related adverse events were common, and some patients achieved complete response during the maintenance phase after partial response in the induction phase.
LEUKEMIA & LYMPHOMA
(2021)
Article
Hematology
Andrew J. Doyle, Matthew J. Stubbs, Will Lester, Will Thomas, John-Paul Westwood, Mari Thomas, Charles Percy, Nithya Prasannan, Marie Scully
Summary: Obinutuzumab and ofatumumab may be considered as alternative options to rituximab in the treatment of iTTP, with a comparable safety profile, absence of significant hypersensitivity reactions, and sustained normalization of ADAMTS13.
BRITISH JOURNAL OF HAEMATOLOGY
(2022)
Article
Clinical Neurology
Huixin Yu, Gordon Graham, Olivier J. David, Joseph M. Kahn, Marina Savelieva, Etienne Pigeolet, Ayan Das Gupta, Ratnakar Pingili, Roman Willi, Krishnan Ramanathan, Bernd C. Kieseier, Dieter A. Haring, Morten Bagger, Per Soelberg Sorensen
Summary: This study used a population pharmacokinetics (PK)-B cell count model to analyze the optimal dosage regimen for the marketed drug ofatumumab. The results showed that the 20mg dose achieved the desired B cell depletion target most effectively and no dose adjustment based on patient characteristics was needed. Only weight had a significant effect on pharmacokinetics, with no clinically relevant effect on B cell levels.
Article
Reproductive Biology
Muriel Bellot, C. Marc Luetjens, Morten Bagger, Courtney Horvath, Esther Sutter, Anthony DeLise, Dominique Brees, Jose M. Carballido, Ratnakar Pingili, Krishnan Ramanathan, Bernd C. Kieseier, Kerstin Hellwig
Summary: This study investigated the effects of ofatumumab on pregnancy, parturition, and lactation in cynomolgus monkeys. The results showed that ofatumumab did not cause maternal toxicity or embryotoxicity, and had no effect on the growth and development of offspring.
REPRODUCTIVE TOXICOLOGY
(2022)
Article
Biotechnology & Applied Microbiology
Carl Grunfeld, Argyris Dritselis, Peter Kirkpatrick
NATURE REVIEWS DRUG DISCOVERY
(2011)
Article
Biotechnology & Applied Microbiology
Christopher J. Logothetis, Eleni Efstathiou, Fil Manuguid, Peter Kirkpatrick
NATURE REVIEWS DRUG DISCOVERY
(2011)
Article
Biotechnology & Applied Microbiology
Timothy K. Huyck, William Gradishar, Fil Manuguid, Peter Kirkpatrick
NATURE REVIEWS DRUG DISCOVERY
(2011)
Article
Biotechnology & Applied Microbiology
Kurt Huber, Bashar Hamad, Peter Kirkpatrick
NATURE REVIEWS DRUG DISCOVERY
(2011)
Article
Biotechnology & Applied Microbiology
Vernon K. Sondak, Keiran S. M. Smalley, Ragini Kudchadkar, Seden Grippon, Peter Kirkpatrick
NATURE REVIEWS DRUG DISCOVERY
(2011)
Article
Biotechnology & Applied Microbiology
Flavio Vincenti, Argyris Dritselis, Peter Kirkpatrick
NATURE REVIEWS DRUG DISCOVERY
(2011)
Editorial Material
Biotechnology & Applied Microbiology
Andrzej Dlugosz, Sid Agrawal, Peter Kirkpatrick
NATURE REVIEWS DRUG DISCOVERY
(2012)
Editorial Material
Biotechnology & Applied Microbiology
Michael W. Stewart, Seden Grippon, Peter Kirkpatrick
NATURE REVIEWS DRUG DISCOVERY
(2012)
Editorial Material
Biotechnology & Applied Microbiology
Peter Kirkpatrick
NATURE REVIEWS DRUG DISCOVERY
(2012)
Editorial Material
Biotechnology & Applied Microbiology
Peter Kirkpatrick
NATURE REVIEWS DRUG DISCOVERY
(2012)
Editorial Material
Biotechnology & Applied Microbiology
Gerard Said, Seden Grippon, Peter Kirkpatrick
NATURE REVIEWS DRUG DISCOVERY
(2012)
Editorial Material
Biotechnology & Applied Microbiology
Richard A. Feelders, Uma Yasothan, Peter Kirkpatrick
NATURE REVIEWS DRUG DISCOVERY
(2012)
Editorial Material
Biotechnology & Applied Microbiology
Ruben A. Mesa, Uma Yasothan, Peter Kirkpatrick
NATURE REVIEWS DRUG DISCOVERY
(2012)
Editorial Material
Biotechnology & Applied Microbiology
Pamela B. Davis, Uma Yasothan, Peter Kirkpatrick
NATURE REVIEWS DRUG DISCOVERY
(2012)
Editorial Material
Biotechnology & Applied Microbiology
Anas Younes, Uma Yasothan, Peter Kirkpatrick
NATURE REVIEWS DRUG DISCOVERY
(2012)
